TITLE PAGE

Transcriptomic Consensus of Atrial Fibrillation Unveils Mechanism-Based Drug Repurposing Opportunities: A Systematic Review and Meta-analysis

Brief Title: Transcriptomic Consensus in Atrial Fibrillation

Sergio Alejandro Gómez-Ochoa[1], Malte Möhn[1,2], Michelle Victoria Malz[3], Roger Ottenheijm[3], Jan D. Lanzer[1,2], Felix Wiedmann[4,5,6], Manuel Kraft[4,5,6], Taulant Muka[7], Constanze Schmidt[4,5,6], Marc Freichel[3], Rebecca T. Levinson[1,2]

1. Internal Medicine and Psychosomatics, Heidelberg University Hospital, 69120 Heidelberg, Germany.
2. Institute for Computational Biomedicine, Heidelberg University Faculty of Medicine, Heidelberg University Hospital, 69120 Heidelberg, Germany.
3. Institute of Pharmacology, Heidelberg University, 69120 Heidelberg, Germany.
4. Department of Cardiology, University of Heidelberg, 69120 Heidelberg, Germany.
5. DZHK (German Center for Cardiovascular Research), Partner Site Heidelberg/Mannheim, University of Heidelberg, 69120 Heidelberg, Germany.
6. HCR, Heidelberg Center for Heart Rhythm Disorders, University of Heidelberg, 69120 Heidelberg, Germany.
7. Epistudia, Bern, Switzerland.

Words count: 7201 words

Funding: The development of this project was funded by the German Research Foundation (Collaborative Research Centre 1550, grant number #464424253 to SAGO, MVM, RO, FW, MK, CS, MF, and RTL), the Informatics for Life Initiative sponsored by the Klaus-Tschirra foundation (MM and RTL), the German Cardiac Society (Research Clinician-Scientist program to FW), the German Heart Foundation/German Foundation of Heart Research (F/03/19 to CS), and the Else-Kröner Fresenius Foundation (EKFS Fellowship and EKFS Clinician-Scientist professorship to CS). The funders had no role in study design, data collection, analysis, interpretation, or report preparation.

Disclosures: None.

Corresponding authors:

Sergio Alejandro Gómez-Ochoa, MD, MSc. Department of General Internal Medicine and Psychosomatics, Heidelberg University Hospital, Im Neuenheimer Feld 672, 69120 Heidelberg, Germany. E-mail address: SergioAlejandro.GomezOchoa@med.uni-heidelberg.de.

Rebecca T. Levinson, PhD. Department of General Internal Medicine and Psychosomatics, Heidelberg University Hospital, Im Neuenheimer Feld 672, 69120 Heidelberg, Germany. E-mail address: rebeccaterrall.levinson@med.uni-heidelberg.de

ABSTRACT

Background and Aims: Despite advances in understanding atrial fibrillation (AF) pathophysiology through the lens of transcriptomics, marked differences in the key AF genes between studies remain, while drugs targeting preserved dysregulated pathways are limited. This systematic review and meta-analysis aimed to provide a consensus transcriptional signature of AF and use it to identify potentially repurposable drugs.

Methods: Bibliographic databases and data repositories were systematically searched for studies reporting gene expression patterns in atrial heart auricle tissue from patients with AF and controls in sinus rhythm. A qualitative synthesis and a transcriptomics meta-analysis were performed. We calculated the pooled differences in individual gene expression to create a consensus signature (CS), from which we identified differentially regulated pathways and estimated transcription factors activity. We also created a protein-protein interaction network to identify drug interactions with highly interconnected genes (hub genes) from the AF-CS.

Results: Thirty-four observational studies were assessed in the qualitative synthesis, while fourteen, comprising 511 samples (338 AF and 173 SR), were included in the meta-analysis. Despite the heterogeneity observed across individual studies, the AF-CS in both chambers were consistent and robust, showing a better performance in classifying AF status than individual studies. The functional analysis revealed commonality in the dysregulated cellular processes across the atria, including extracellular matrix remodeling, downregulation of cardiac conduction pathways, metabolic derangements, and innate immune system activity processes. Finally, drug-gene analyses highlighted several compounds as repurposing drug candidates for AF, highlighting lipid-lowering agents, antioxidants, and retinoids, among others.

Conclusions: Despite variability in individual studies, this meta-analysis elucidated conserved molecular pathways involved in AF pathophysiology across its phenotypes, offering robust and potentially generalizable diagnostic biomarkers. From this AF-CS, we identified potential compounds targeting these dysregulated pathways, thereby addressing an extant gap in AF-specific pharmacotherapy.

Keywords: Atrial Fibrillation; Transcriptomics; Meta-analysis; Pathophysiology, Drug-gene Interactions.

STRUCTURED GRAPHICAL ABSTRACT

Key Question:

Can a meta-analytically derived consensus transcriptional signature effectively capture the core molecular mechanisms underlying AF and serve as a basis for identifying novel drug candidates targeting these conserved pathways?

Key Findings

Extracellular matrix remodeling, downregulation of cardiac conduction pathways, and modulation of innate immune system activity emerged as conserved molecular hallmarks across the AF spectrum. Drug-gene interaction analyses highlighted the repurposing potential of lipid-lowering agents, antioxidants, and retinoids, among other compounds, for targeted intervention in these dysregulated pathways.

Take Home Message

Despite AF's complexity, a transcriptional signature derived through a meta-analysis can pinpoint conserved molecular pathways across AF phenotypes. These insights provide a foundation for identifying and repurposing drugs targeting the core dysregulated processes in the disease, offering new avenues for targeted, mechanism-based treatment of AF.

GRAPHICAL ABSTRACT

Abbreviations: AF: Atrial Fibrillation; LAA: Left Atrial Appendage; RAA: Right Atrial Appendage; CS: Consensus Signature.

Introduction

Atrial fibrillation (AF) is the most prevalent sustained arrhythmia worldwide[1]. It is associated with substantial quality of life deterioration and a high risk of adverse clinical outcomes, including thromboembolic events and mortality[2]. AF is a heterogeneous disease that arises in combination with other cardiovascular diseases, such as hypertension and heart failure, and significantly contributes to chronic disease burden on the individual and the healthcare system[3,4]. Despite the broad array of available diagnostic tools and therapeutic interventions, recurrent AF, treatment resistance, and adverse side effects of current pharmacotherapies remain pressing challenges in this setting[5]. Moreover, current therapies do not explicitly target AF's molecular and genetic contributors, leading to a one-size-fits-all approach that often overlooks the patient's individualized pathophysiology[6]. Therefore, a more complete understanding of its underlying molecular and genetic contributors has become essential[7].

In the past two decades, advances in molecular biology methodologies and 'omic' technologies have paved the way for more precise investigations into the pathophysiology of AF. Among these methods, transcriptomic analyses have emerged as a valuable tool for probing AF's genetic and molecular foundations[8]. However, a significant gap in the existing research landscape is the lack of comprehensive studies considering the entire transcriptome[9–13]. When studies consider the complete transcriptome, they often still focus on identifying specific genes, which may vary widely between studies, resulting in noteworthy variations in the key AF genes identified[14]. Technical differences between experiments may partially explain these disparities; however, contrasts in sociodemographic and clinical features, such as age, gender, ethnicity, comorbidities, and AF type, between cohorts also represent a relevant source of variation in the observed trends[15]. Consequently, these factors may inadvertently influence the gene expression profiles associated with this multifactorial disease, result in patient- or population-specific genomic responses, and affect the expression levels of genes involved in the etiology of AF[16]. This fragmentation and heterogeneity in the available evidence have led to a necessity for a consensus transcriptional signature, which could provide a more unified perspective on the molecular processes that instigate and perpetuate this disorder, offering relevant insights into the disease and laying the groundwork for more personalized and effective treatment strategies[17].

This consensus signature meta-analytical approach using transcriptomic data has been previously applied in studies evaluating cardiac tissue from patients with heart failure (HF) and renal tissue from patients with chronic kidney disease, validating the feasibility of combining RNA-sequencing and microarray data from different sources, platforms, and conditions, as well as providing a statistical framework applicable in other contexts[18,19]. In light of this, the primary aim of our study was to

develop a consensus transcriptional signature for the left- and right atrial appendages in AF. To accomplish this, we undertook a systematic review and meta-analysis of existing studies comparing myocardial gene expression patterns in patients diagnosed with AF and control subjects, presumably in sinus rhythm (SR). Furthermore, we aimed to leverage the identified signature and translate it into potential drug candidates for AF by evaluating consensus signature-derived hub genes and extrapolating possible critical regulatory elements in AF pathophysiology that may serve as putative targets for pharmacological intervention.

Methods

Systematic Review

Search strategy and selection criteria.
We followed two recent guidelines for the conduct of the systematic review and meta-analysis and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for reporting **(Supplemental Table 1)**[20–22]. The protocol of this study is registered in the PROSPERO database with the record code CRD42023399021.

At first, MEDLINE/Ovid, EMBASE/Ovid, CINAHL/EBSCOhost, and Google Scholar were searched to identify relevant studies from January 1st, 2000, until April 30th, 2023, without language restrictions. Search terms related to AF transcriptomics were used, including atrial fibrillation, atrial cardiomyopathy, transcriptome, microarrays, and RNA-Seq, among many others. The complete search strategy is described in **Supplemental Text 1**. All observational studies comparing the transcriptomic profile (by microarrays or RNA-Seq) of patients with a diagnosis of AF with individuals suspectedly in SR were included. Only studies that assessed differential gene expression between AF and SR groups by analysis of myocardial tissue samples were included.

Database screening and data extraction
Four reviewers screened titles and abstracts in duplicate to systematically identify potentially includable studies according to the selection criteria. Subsequently, four reviewers independently extracted the following data from each included study: name of the first author, the country in which the study was performed, year of publication, study design, the total number of patients, number per group (AF vs. SR), demographic characteristics of the population evaluated, type of AF evaluated, left ventricular ejection fraction, sample sources, sequencing and analysis methods, and differentially expressed genes between groups.

Quality assessment

Four authors independently assessed each study in duplicate using an adapted version of the Checklist for Analytical Cross-Sectional Studies from the Joanna Briggs Institute (JBI) (**Supplemental Table 2**). This adapted checklist was designed due to the lack of specific quality assessment tools for studies performing unbiased transcriptomic analysis in tissue samples and allowed an objective assessment of relevant methodological and reporting aspects of unique importance in this type of studies. It comprises ten items covering study design and participant characterization, sample processing, statistical analysis, and data reporting. Conflicts were resolved by consensus or the intervention of an additional reviewer.

Consensus Transcriptional Signature Meta-analysis

Datasets search

In parallel to the studies search, we queried four databases that store biomedical studies datasets: the Gene Expression Omnibus database, the European Nucleotide Archive, ArrayExpress, and the European Genome Phenome Archive. The following search terms were used: "atrial fibrillation," "atrial cardiomyopathy," "atrial arrhythmia," and "afib." We included a dataset if it assessed myocardium samples, if data from at least four total patients were available, and if there was a protocol describing sample gathering and processing methodology available. **Supplemental Figure 1** summarizes the main steps in the analysis process of this study, which were developed based on previously published statistical frameworks and will be presented in detail in the following sections[18,19].

Data processing

The raw data from studies found through the systematic search strategy and from queried repositories were downloaded and processed uniformly. Non-normalized count matrices were downloaded directly, whereas, for studies with only sequencing files (.fastq files), sequence alignment was performed using the HISAT2 alignment algorithm to acquire count matrices for data derived from RNA-Seq experiments. Standard processing and normalization were performed using the limma package for datasets derived from RNA-seq, while the oligo package was also used for those derived from microarrays.

Sample classification and contrasts

We classified the collected samples according to AF rhythm (AF vs. SR) and according to sample origin (left atrial appendage and right atrial appendage [LAA and RAA, respectively]). From this, the differential gene expression between AF and SR in each chamber was analyzed.

Consistency of transcriptional signatures

Using an inferential approach, we estimated the accuracy of using individual studies to classify samples of other studies into either "AF" or "SR" categories. For this purpose, a disease score was calculated by linearly combining the t-values of the differentially expressed genes of the reference studies (disease pattern) with their expression values in the individual test study. This was built assuming that if two or more studies share AF transcriptional signatures, the disease score derived from these could be used to discriminate between sample groups in other independent datasets accurately. Therefore, this disease score would estimate how similar the expression profile observed in each sample with the disease phenotype is, going beyond changes in the mean expression of specific genes and focusing on the joint regulation of multiple genes.

The number of disease classifiers built was the same as the total study number for each comparison based on the t-values of the differentially expressed genes in each contrast. Once each sample-level disease score was calculated, the area under the receiver operating characteristic curve (AUROC) was used to test the score's accuracy to discriminate samples from AF patients, reflecting the conservation of gene regulation patterns across studies. Finally, the consistency of the direction of transcriptional regulation in the disease score results was also assessed by separating the top differentially expressed genes based on their regulation direction and performing gene set enrichment analysis (GSEA).

Meta-analysis

Overall, a consensus transcriptional signature meta-analysis can be defined as an approach to identify consistent gene expression patterns (transcriptional signatures) across multiple independent studies focusing on a particular condition[18,19]. This approach allows for the identification of more robust and reliable molecular signatures, potentially elucidating pivotal transcriptional programs consistently correlated with specific states or responses, such as disease onset, progression, or reaction to specific interventions. For this purpose, a Fisher's combined probability test was used to pool the differential expression analysis results per individual genes if they were evaluated in at least 50% of the studies. For each contrast, the degrees of freedom for the statistical tests were derived from the number of studies included. Since none of the included studies mentioned having performed any probabilistic sampling procedure, additional study weighting was not performed. After the Benjamini-Hochberg (BH) correction of the pooled P values, a gene ranking representing the AF transcriptomic signature was generated[23]. Finally, we wanted to understand the consistency of results for each gene by looking at each study's top 500 genes that showed the most significant differences in activity when comparing AF vs. SR and then, by employing GSEA, comparing them with the AF consensus signature. This helped us determine if the list of top 500 differentially expressed genes from each study significantly overlapped with the genes in the atrial fibrillation consensus signature (AF-CS) by providing an enrichment score, which essentially informs how much the individual study's top 500 genes align with the top results of the AF-CS.

In addition, we assessed the concordance of the top 500 genes of each chamber's consensus signature using the Jaccard index. Complementarily, we compared the consensus rankings of LAA and RAA using the Rank-Rank Hypergeometric Overlap (RRHO) test. This threshold-free algorithm detects common trends between two ordered lists of differentially expressed genes. In this method, the genes are ordered based on the product of the negative logarithm (base 10) of the differential expression p-value and the effect size direction[24]. According to this ranking, genes with unchanged, upstream, and downstream effects are positioned in the middle, at the top, and at the bottom of the list, respectively. The degree of similarity between the gene lists from two different datasets is then quantified through a one-sided p-value, which is determined using the principles of the hypergeometric distribution.

Sensitivity analysis

Using a leave-one-out procedure, we evaluated how much each study impacted the overall findings. Therefore, the meta-analysis for each contrast was repeated the same number of times of the amount of studies present, each time leaving out the data from one study. After each round of analysis, we performed a Spearman rank correlation test comparing the leave-one-out result with the full meta-analysis to test the influence of the left-out study. A correlation value close to 1 would indicate that the results were almost identical, and therefore, the excluded study did not significantly impact the overall findings. Conversely, a low correlation value would highlight the studies that strongly influenced the meta-analysis. This approach allowed us to assess the robustness of the meta-analysis ranking rigorously.

Added value of the meta-analysis

To analyze the benefit of combining the available transcriptomic data related to AF in our meta-analysis, we examined whether the top 500 genes identified from the consensus signature provided a more representative transcriptional 'fingerprint' of AF than the top 500 genes picked from each study. In particular, we checked whether the AUROCs based on the consensus genes were significantly better than those derived from individual studies using the Wilcoxon paired test. At first, we divided the top 500 genes into two groups: those up- and down-regulated in AF. We then checked for their presence in each individual study's gene activity ranking using GSEA. Then, we compared these enrichment scores to the ones obtained using the top 500 genes from each separate study with the Wilcoxon paired test.

Functional analysis

After the meta-analysis, each gene resulting -log10 p-value was weighted based on the mean direction of change across the studies to develop the directed consensus signature. From these results, gene

ontology terms, miRNA targets, and pathways from the Molecular Signatures Database (MSigDB) were used to enrich the signature using the *msigdbr* package. In parallel, the activity of transcription factors (TF) was appraised using DoRothEA. Furthermore, signaling pathways activity was estimated using PROGENy. P values adjusted with the BH procedure were computed for each test.

Tissue-cell-type enrichment of the AF-CS

Using the differentially expressed genes (BH p-value < 0.05) in each CS, we aimed to explore the potential cellular context in each chamber using WebCSEA. This tool provides a specialized query interface for analyzing gene sets against an extensive repository of cell expression profiles specific to various human tissue types. For each query run, the system produces a series of analytical metrics, including the raw statistical significance value (p-value) specific to cell type enrichment analysis (CSEA), a consolidated p-value derived using a permutation-based statistical approach, and a list of shared genes between the query set and the cell type-tissue-specific expression profiles.

Protein-protein interaction network and Hub genes identification

Using the consensus signature from each chamber, protein-protein interaction (PPI) networks were created using the Search Tool for the Retrieval of Interacting Genes (STRING) version 12.0. The PPIs with confidence scores of at least 0.4 were selected and imported to Cytoscape (version 3.10.0) to proceed with hub genes selection using the cytoHubba plugin. To estimate the ideal number of hub genes to included, the maximum clique centrality (MCC), maximum neighborhood component (MNC), and density of maximum neighborhood component (DMNC) methods were used to create five hub genes networks each, consisting of the top 10, 20, 30, 40, and 50 hub genes. The networks for each method were then evaluated for hub genes consistently present in the three resulting networks in each group (top 10, top 20, top 30, top 40, and top 50 hub genes). After this step, we selected the hub genes derived from the best network threshold based on the number of conserved genes observed in the three methods (between 8 and 15).

Hub gene-drug network analysis

To identify molecules that could potentially interact with the previously identified hub genes, the Comparative Toxicogenomics Database (CTD; available at: http://ctdbase.org/) was queried using the "Batch query" tool. We limited the queried molecules to include only curated chemical-gene interactions observed in human or mice/rat models (Mus Musculus/Rattus Novegicus). Finally, molecules that interacted with at least five hub genes and have been approved by the FDA for use in humans or previously investigated as potential therapeutic agents *in vitro* or in animal models were manually selected for further analysis.

Results

Systematic Review

Of the 1243 references screened, 34 studies fulfilled the selection criteria and were incorporated into the systematic review **(Figure 1)**[13,25–57]. The selected studies were published between 2005 and 2022, with the majority (20 [58.8%] of 34) published within the past five years. The studies collectively examined 1,680 patients, with a range of 5 to 280 patients per study, and were primarily performed in Asia (n=16) and Europe (n=13) **(Table 1)**.

Figure 1. Flowchart of study selection.

The pooled mean age of the AF groups (Pooled mean age 62.7 years; 95% confidence interval [CI] 59.4-66.0. I^2: 48%) was higher than that of the SR groups (Pooled mean age 56.9 years; 95% CI 51.1-62.8. I^2: 72%), a statistically significant difference (Mean Difference [MD] 3.84 years; 95% CI 1.20-6.48. I^2: 78%) **(Supplemental Figure 2)**. The pooled male prevalence observed in AF groups (Pooled prevalence [PP] 67%; 95% CI 60-75. I^2: 55%) **(Supplemental Figure 3)** was similar to the one in the SR populations (PP 65%; 95% CI 57-73. I^2: 51%) **(Supplemental Figure 4)**. Furthermore, although non-significant, we observed a trend towards a lower left ventricular ejection fraction (LVEF) in the AF group compared to the SR one (MD -2.42%; 95% CI -5.40-0.55. I^2: 65%) **(Supplemental Figure**

5). Most of the studies included patients with persistent AF (n=17), followed by permanent (n=13) and paroxysmal AF (n=8). The primary sample sources for these studies were the left (n=30) and right atrial appendage (n=28) **(Table 1)**.

Regarding technology and platforms, both microarray (n=16; 47%) and RNA-Seq (n=18; 53%) technologies were utilized, with the Illumina HiSeq series and Affymetrix platforms the most commonly employed **(Table 1)**. The number of differentially expressed genes (DEGs) reported in the studies ranged widely, from 39 to 7566 **(Table 1)**, with a median of 296 DEGs per study. Furthermore, when pooling the DEGs according to the direction of expression, around 49% (95% CI 35-63. I^2: 99%) were up-regulated in AF, while around 51% (95% CI 37-65. I^2: 99%) were down-regulated compared with controls.

Quality of included studies

After applying our adapted 10-point version of the JBI Checklist for Analytical Cross-Sectional Studies, we observed a mean score of 7/10 points for the included studies (Quartile 1: 6; Quartile 3: 8), with only one study (3%) scoring less than four points **(Supplemental Table 2)**. This result highlighted the adequate reporting rate of the included studies for relevant aspects related to transcriptomic analysis.

Consensus Transcriptional Signature Meta-analysis

Of the total number of studies included in the quantitative analysis, 14 met the criteria for inclusion in the transcriptional consensus meta-analysis[25,27,30,31,33–35,44–48,52,57]. The data sets derived from these studies consisted of a total of 511 samples (338 AF and 173 SR) from 466 patients (mean age 58.5 years; 58% male) **(Supplemental Table 3 and Supplemental Figure 6)**. Most samples were collected in the context of valve surgery, followed by coronary artery bypass grafting (CABG) surgery and cardiac transplantation. The majority of studies included patients with permanent or persistent AF, with only three including patients with paroxysmal AF **(Supplemental Table 3)**. **Figure 2** summarizes the general characteristics of the studies included in the meta-analysis, explicitly highlighting the reporting of relevant information **(Figure 2A)** and the sample sizes evaluated **(Figure 2B)**. Unfortunately, only a small minority of studies reported individual information on the included patients, which limited the performance of analyses by relevant covariates. From the total studies, 11 analyzed samples from the LAA, while seven analyzed samples from the RAA **(Supplemental Table 3)**. The following sections will describe the AF-CS results for each evaluated cardiac chamber (LAA-AF-CS and RAA-AF-CS).

Figure 2. Summary of overall study characteristics.

A, Available metadata on relevant characteristics in the included datasets. **B,** Sample size per group categories.

Abbreviations. Ind: Individual-patient data; Gr: Group data (measures of central tendency and dispersion); NR: Not reported.

Overall characteristics and consistency measures

Gene coverage analysis highlighted higher comparability of the LAA samples (mean Jaccard index of ≈0.70) than those taken from the RAA (mean Jaccard index of ≈0.49) (**Supplemental Figure 7**). The ANOVA test revealed a significant association between the technology type ("RNA-Seq" vs. "Microarrays") and the first three PCs of the z-transformed samples (P<0.05 for the first three PCs in both atria) (**Supplemental Figure 8**). However, after performing gene standardization, the heterogeneity derived from technical aspects was significantly reduced. Considering the relevance of clinical and sociodemographic parameters in the observed results, we evaluated the proportion of variance explained by age, sex, and left ventricular ejection fraction (LVEF) in standardized PCA. We observed that the proportion of men in the different groups was not associated with any principal component, explaining zero percent of the variance. On the other hand, the mean age in each group (AF and SR) explained 3.5% of the variance in LAA and 4.9% in RAA, whereas mean LVEF explained 4.5% in LAA and 8.4% in RAA. In comparison, the variance explained by AF diagnosis was higher, at 7.9% in the LAA and 16.5% in the RAA (**Supplemental Figure 9**).

We then evaluated how consistent the results of the studies were concerning the genes that ranked highest after differential expression analysis (**Supplemental Figure 10**). For this, we compared the

top 500 genes in each individual study, observing an extremely low concordance in the results of both cardiac chambers regarding the mean values of the Jaccard Index (LAA: 0.02 and RAA: 0.03) **(Supplemental Figure 11A and B)**. However, when evaluating the predictive capacity of these top 500 genes of each study to discriminate the diagnosis of AF in other datasets using the disease score, we observed a relatively high performance according to the median AUROC values (LAA: 0.74 and RAA: 0.77) **(Supplemental Figure 11C and D)**.

As the molecular responses showed some degree of uniformity across the evaluated studies, we examined whether the direction of differential regulation of the top DEG in each dataset was consistent with their observed trends in the remaining studies. For this purpose, an independent enrichment analysis was performed on the gene-level statistics derived from the top 500 up- and down-regulated genes from each study **(Supplemental Figure 11)**. This enrichment score (ES) measures how much the top DEG in one study is over-represented among the top DEG in all the other studies. A positive score means that a gene is often found to be more active in AF across multiple studies. Conversely, a negative score would mean that a gene is often found to be less transcribed in AF samples across these studies. Thus, the ES serves as a consistency checker across multiple studies for the direction of gene regulation. In our results, the median ES for the differentially up-regulated genes in the LAA and RAA-AF-CS were 0.38 and 0.30, respectively **(Supplemental Figure 11E and F)**. On the other hand, the ES values for the down-regulated genes in the LAA and RAA-AF-CS were -0.37 and -0.33, respectively **(Supplemental Figure 11G and H)**.

Moreover, a significant correlation between the AUROC values of disease score categories and enrichment scores for DEG was observed for both the LAA-AF-CS (Pearson correlations of 0.77 for up-regulated genes [p<0.001] and -0.67 for down-regulated genes [p<0.001]) and the RAA-AF-CS (Pearson correlations of 0.80 for up-regulated genes [p<0.001] and -0.73 for down-regulated genes [p<0.001]). This finding suggests that, despite study-specific variations, the direction of gene activity changes was generally consistent across studies. Additional analyses showed similar results when different numbers of top genes were selected (50, 100, 200, 500, and 1000) **(Supplemental Figure 12)**.

Meta-analysis of transcriptional signatures in AF
We developed the AF-CS for each atrial chamber by pooling the individual-study results of 21722 genes for the LAA and 11782 for the RAA contrasts using the Fisher's Method **(Supplemental Table 3)**. This consensus ranking represents the overall differential gene regulation patterns across the AF spectrum, highlighting genes consistently deregulated in common directions over multiple studies **(Supplemental Figure 13)**. In the LAA, 650 genes showed a BH p-value < 0.05; this number was 212 for the RAA analysis **(Supplemental Table 3)**. Several genes related to structural cardiac

remodeling processes were observed among the top positions of the AF-CS in both cardiac chambers, including COLQ, ANGPTL2, LBH, and COL21A1[58–61]. Other genes near the top of the consensus included those involved in myocardial electrical remodeling processes, such as CACNA1G, HCN4, and KCNK3[62–64]. Multiple genes related to the activity of the innate immune system were also found to be significant and highly ranked in the AF-CS, especially in the LAA, with ASAH1, CKAP4, STING1, and FCER1G standing out. Finally, new genes not previously related to AF in the literature were identified as occupying leading positions in the consensus, including DHRS9, CRTAC1, RASL11B, and GRIP2 **(Supplemental Figure 14)**.

The leave-one-out sensitivity analysis confirmed the robustness of the overall ranking results (mean Spearman rank correlation: LAA=0.96 and RAA=0.94) **(Supplemental Figure 15)**. Furthermore, there were no significant associations between the sample size of each analyzed study and the enrichment of its specific DEG in the higher positions of the CS (LAA: Spearman correlation, 0.58, P=0.07; RAA: Spearman correlation, 0.65, P=0.11). Despite the small sample sizes observed in some studies, this result indicated that most studies were robust enough to provide real biological insights from the contrasts performed.

When analyzing the top 500 genes of each individual chamber's consensus signature, we observed a low concordance of the genes occupying these positions (Jaccard index value: 0.17). However, a threshold-free approach (RRHO test) of the whole gene rankings revealed a significant overlap in both directions of gene expression between the two chambers, highlighting a robust overall concordance between the two signatures **(Supplemental Figure 16)**.

Moreover, we assessed the added value of performing a transcriptional consensus meta-analysis in this context by comparing the performance of the disease score constructed using the top 500 meta-analysis genes vs. individual studies. We observed superior predictive performance of the measures derived from the meta-analysis in both LAA (mean AUC AF-CS: 0.82 vs. mean AUC individual studies: 0.74. p<0.001) and RAA (mean AUC AF-CS: 0.90 vs. mean AUC individual studies: 0.77. p<0.001). Similarly, the mean enrichment scores obtained from the AF-CS results were significantly better compared to the ones from individual studies for both up-regulated genes (LAA: mean ES 0.52 vs. 0.38. p<0.001; RAA: mean ES 0.47 vs. 0.30. p<0.001) and down-regulated genes (LAA: mean ES -0.42 vs. -0.33. p=0.002; RAA: mean ES -0.50 vs. -0.37. p<0.001). When testing whether the top meta-analysis genes of each chamber's AF-CS could predict the disease condition in samples from the other chamber, we observed significantly better performance in terms of the median AUC compared with the pairwise classifier from individual study data (LAA CS in RAA samples: 0.89 vs. individual RAA studies: 0.77. p<0.001; RAA CS in LAA samples: 0.77 vs. individual LAA studies: 0.74. p<0.001). These results suggested more consistent biological signals with the meta-analysis results

over individual analyses and supported the presence of common gene expression patterns in both chambers.

Functional analysis of the AF-CS

The AF-CS results allowed us to characterize the cellular processes consistently deregulated in AF. To this end, we estimated the activity of transcription factors, signaling pathways, and miRNAs in each of the cardiac chambers using a gene set enrichment analysis approach (**Figure 3**). We found significant enrichment for the LAA consensus signature for 366 Gene Ontology terms, 28 Hallmark gene sets, 42 Reactome pathways, and 25 KEGG pathways (**Supplemental Table 3**). Positively enriched gene sets in this chamber were predominantly related to epithelial-mesenchymal transition, extracellular collagen matrix organization, and cytoskeletal regulation. In contrast, negatively enriched sets were associated with diverse processes related to electrical/muscle function, neuronal signaling, muscle contraction, and ion channel complexes. On the other hand, the number of results in the RAA-AF-CS enrichment was lower, with only 27 significantly enriched Gene Ontology terms. These included upregulated processes related to extracellular collagen matrix organization; however, most of the enriched terms were observed to be downregulated in the AF group, highlighting cardiac conduction, autonomic function, action potential, and cell-cell signaling processes. When comparing the top results between the chambers, collagen extracellular matrix organization processes were significantly upregulated in both atrial appendages during AF, underlining the role of extracellular matrix remodeling in AF pathophysiology. On the other hand, processes related to normal cardiac conduction and signaling mechanisms were universally downregulated in AF. Notably, we did not find processes that were significantly upregulated in LAA and simultaneously downregulated in RAA, or vice versa, suggesting that differential regulation of processes between atrial appendages, if present, is likely to be nuanced.

Furthermore, the inferred transcriptional activity of 754 transcription factors (TF) allowed us to identify 100 differentially active TF in the LAA and 53 in the RAA. At the same time, 100 and 49 miRNAs were differentially enriched in AF patients in the LAA and RAA contrasts, respectively (**Supplemental Table 3**). Finally, pathway analysis reported the up-regulation of the TGFβ, JAK-STAT, Hypoxia, and WNT pathways in the LAA, with a simultaneous down-regulation of the PI3K, TRAIL, EGFR, NFkB, and Estrogen pathways in this chamber. In contrast, the RAA results suggested an up-regulation of the TGFβ, EGFR, MAPK, and VEGF pathways, while the Androgen and JAK-STAT pathways were observed to be downregulated. These results highlighted the divergent transcriptional landscapes and the potential chamber-specific molecular changes that underlie the complexity of atrial fibrillation pathophysiology (**Supplemental Table 3 and Figure 3**).

Figure 3. Functional analysis results of the AF-CS in each cardiac chamber.

Bar length indicates the statistical significance of the specific item (gene set, miRNA, TF, pathway) enrichment (–log10 BH P‑values) with the vertical dashed line indicating the statistical significance threshold (Benjamini‑Hochberg P=0.25) and bar color indicating the direction of enrichment (A, B, E, and F) or the direction of activation (C, D, G, and H). Top 25 (A) most enriched canonical, ontology, and hallmark gene sets, along with Reactome and KEGG pathways, (B) miRNAs' targets, (C) transcription factor activities, and (D) signaling pathway activities in each direction from the LAA AF-CS. Top 25 (E) most enriched canonical, ontology, and hallmark gene

sets, along with Reactome and KEGG pathways, (F) miRNAs' targets, (G) transcription factor activities, and (H) all signaling pathway activities in each direction from the RAA AF-CS.

Tissue-cell-type enrichment of the AF-CS

To get insights into how processes enriched in the AF-CS may relate to the function of individual cell types, we performed a tissue- and cell-type-specific enrichment analysis using WebCSEA (see Methods). At the selected Bonferroni-corrected significance threshold (p = 3.69 x 10^-5), the signatures of two sets of fetal cardiomyocytes were significantly enriched in the LAA CS (Fetal_HCA_Heart_Cardiomyocytes: p-value= 8.43 x 10^-6 and FetalHeart_Ventricle cardiomyocyte: p-value= 2.63 x 10^-5), while the signatures of a fibroblast cell-type (AdultArtery_Fibroblast: p-value= 1.61 x 10^-5) and a fetal mesenchymal progenitor (FetalBrain_Fetal mesenchymal progenitor: p-value= 2.67 x 10^-5) were significantly enriched in the RAA CS **(Supplemental Figure 17)**. These results highlight the reactivation of fetal cellular programs during the cardiac remodeling process in AF-affected atria.

Protein–protein interaction (PPI) networks and Hub genes analysis

Furthermore, PPI networks were created to identify Hub genes, consisting of 628 nodes and 1627 edges in the LAA (PPI enrichment p-value<0.0001) and 212 nodes and 296 edges in the RAA consensus signature (PPI enrichment p-value<0.0001) **(Supplemental Figure 18)**. From the hub genes selection approach (see Methods), we observed that evaluating the top 50 hub genes with each method in the LAA AF-CS allowed us to identify nine hub genes (C1QB, C1QC, CACNA1G, COG3, COPG1, KDELR3, SEC31A, and TNNI1) consistently present in the three networks generated by each method individually. The result for the RAA AF-CS was 14 hub genes (BMP7, CACNA1D, CACNB2, CHL1, FBN2, FGF1, FGF7, HSPA2, KCND3, PLP1, RPS6KA5, TGFBR2, TNNI3, TNNT1), which were present in the three networks generated after selecting the top 30 hub genes in each method. According to the enrichment analysis using Gene Ontology, Reactome, and KEGG, these genes are involved in processes such as cardiac contraction and electrical activity, immune response and inflammation, cellular growth, repair, and remodeling, as well as intracellular transport and protein maintenance. When testing the performance of using these hub genes to classify AF and SR across the included datasets, we observed slightly higher median AUC values compared with the classifiers using the top 500 genes in each individual study; however, the overall differences were not statistically significant (LAA: 0.77 vs. 0.74. p=0.351; RAA: 0.86 vs. 0.77. p=0.142).

Hub gene-drug network analysis

Three hundred seventy-one chemical compounds interacting with the LAA hub genes and 725 with the RAA hub genes were retrieved from the CTD. After manual curation of the compounds (see Methods), 17 molecules (9 compounds from the LAA and 12 from the RAA consensus signatures) exhibited sufficient potential to be postulated as therapeutic options in the treatment of AF **(Supplemental Figure 19 & Table**

2). **Supplemental Table 4** summarizes the evidence available in the literature on the mechanisms of action and potential therapeutic benefits of these curated molecules.

Discussion

The present consensus transcriptional meta-analysis included 511 samples from 466 patients in 14 studies, representing the largest meta-analysis of transcriptomic data in atrial fibrillation performed to date. The robust consensus gene rankings developed for LAA and RAA contrasts revealed a consistent dysregulation in genes involved in structural and electrical cardiac remodeling, also uncovering novel genes not previously associated with AF. Furthermore, functional analysis delineated consistently deregulated cellular processes such as epithelial-mesenchymal transition and collagen extracellular matrix organization, while tissue-cell-type enrichment analysis highlighted a significant enrichment of fetal cardiomyocytes in the LAA and fibroblast and fetal mesenchymal progenitor cells in the RAA. Finally, hub gene identification and gene-drug network analysis pinpointed drug candidates with the potential for repurposing in AF treatment. Despite the methodological challenges of meta-analyzing clinical data, our work highlights the value of integrating heterogeneous transcriptomic datasets to identify conserved molecular pathways, thereby contributing to our understanding of AF pathophysiology and providing additional information for developing novel mechanism-based therapies.

Considering the complex pathophysiological landscape of AF, identifying conserved molecular mechanisms and cellular responses from a transcriptomics perspective represents a significant opportunity to improve our understanding of the phenomena underlying this arrhythmia (**Figure 4**)[65]. Overall, the main processes highlighted in the consensus were related to the structural remodeling of the myocardium, similar to the molecular changes observed in the development and progression of heart failure at the ventricular level[19]. In particular, the functional analysis highlighted the relevance of epithelial-mesenchymal transition (EMT), a widely studied process in HF[66]. EMT is characterized by the reactivation of a fetal cellular program involving the expression of embryonic markers in response to myocardial injury[66]. This phenomenon was observed in the results of the cell type-specific enrichment analysis of both AF-CS, suggesting the emergence of cells with a fetal-like phenotype in the AF atria, at least from a genomic perspective. Furthermore, epicardial EMT in response to injury is also associated with increased fibroblast activation and their transformation into myofibroblasts under pathological stress, a finding consistent with the observed enrichment of extracellular matrix-related processes and the fibroblast cell type[66]. The resulting structural alterations and fibrosis development leads to conduction disorders and the reentry phenomena characteristic of AF[65].

Figure 4. Pathophysiological perspective of AF from conserved dysregulated processes identified in the AF consensus signature.

Electrophysiological remodeling and calcium (Ca^{2+}) handling anomalies were also consistently observed in AF tissues, underlining significant dysregulation of key potassium (KCNK3, KCNN2, KCNQ4, KCNJ5, KCND3) and calcium (CACNA1G, CACNA1D, CACNB2, CACNA2D2) channels. These findings were reflected in the significant enrichment of processes pertaining to the action potential, voltage-gated channel activity, and cardiac conduction, all of which were among the top downregulated pathways in both atria. Prior studies have characterized the electrical remodeling present in AF, highlighting the relevance of action potential duration (APD) heterogeneity in the initiation and persistence of reentrant arrhythmias in AF[67,68]. In this regard, the study of *Avula et al.* observed that early afterdepolarizations alone failed to initiate AF in the absence of APD heterogeneity using a gain-of-function NaV1.5 mice model, suggesting the critical role of electrical remodeling and the presence of an "appropriate" atrial substrate for the development of the arrhythmia[69]. Concurrently, Ca^{2+}-handling abnormalities, highlighting RyR2 dysfunction, altered L-type Ca^{2+} currents, and increased spontaneous Ca^{2+} release from the sarcoplasmic reticulum have been implicated as key drivers of AF[70]. Our results are in line with these findings, revealing a conserved dysregulation in critical calcium channels and associated proteins (S100A8, S100A9, SMOC-2) in AF atria, which may support the synergistic role of abnormal Ca^{2+} signaling and structural remodeling in failing cardiomyocyte adaptation to abnormal calcium influx and overload derived from rapid atrial stimulation, thereby facilitating the arrhythmia onset and perpetuation[71].

Concomitant with electrical and structural remodeling, our findings suggest the presence of metabolic reprogramming processes in AF. These are closely related to EMT, as studies performed in failing hearts have shown that the fetal phenotype is characterized by a "switch back" to glycolysis as the primary energy source of the cardiomyocytes rather than oxidative metabolism[72]. However, this change may not be straightforward, as the results of our functional analysis suggested an increase in both the activity of oxidative phosphorylation and glycolysis pathways. This apparently discordant finding is consistent with the results of two proteomic studies that reported the upregulation of proteins involved in fatty acid uptake into the mitochondria and β-oxidation, such as fatty acid translocase (FAT/CD36), (14)C-palmitic acid and CD36, which resulted in an apparent increased activity of the oxidative phosphorylation pathway in the AF groups[73,74]. Conversely, they also demonstrated decreased expression and activity in proteins pivotal to oxidative phosphorylation, the TCA cycle, and, notably, the electron transport chain[73,74]. This dichotomy underlines a potentially maladaptive metabolic response to the chronic energy stress inherent in AF, emphasizing that cellular efforts to augment energy production via selective protein upregulation are insufficient to offset inherent mitochondrial derangements in ATP synthesis that result from the persistently high energy demand present in AF[75,76].

The present consensus signature analysis also provided relevant insights regarding the role of the innate immune system in AF, highlighting neutrophil degranulation as the top-ranking Reactome pathway in the LAA-CS. This finding is supported by current evidence published in the literature, which highlights increased neutrophil extravasation in the atria of AF patients, in addition to observing significant colocalization between enzymes such as myeloperoxidase and areas of atrial myocardial fibrosis[77–79]. On the other hand, the neutrophil-lymphocyte ratio has been shown to perform favorably in predicting de novo AF, as well as relevant clinical outcomes such as stroke[80–82]. Our results extend these findings across the spectrum of AF, highlighting the activity of the innate immune system as a preserved process of potentially great importance in the development and persistence of this arrhythmia.

Finally, our integrative analysis of pharmacogenomic networks identified drug candidates for AF prevention and treatment, being mostly FDA approved molecules or available as dietary supplements, highlighting lipid-lowering compounds, antioxidants, and retinoids. By leveraging a consensus-based gene signature, our methodology enhances the external validity of gene-drug interaction networks, thus improving the generalizability of the results. **Table 2** synthesizes the existing literature on the mechanistic and clinical evidence of these molecules in AF settings. Among these, lipid-lowering agents have been perhaps the most studied in this setting, showing promising efficacy in reducing AF incidence, independent of lipid levels, suggesting secondary anti-inflammatory and antioxidant benefits[83,84]. Correspondingly, compelling evidence has highlighted the therapeutic potential of

antioxidants—namely ascorbic acid, curcumin, resveratrol, and genistein—in the context of AF. These agents can modulate a myriad of molecular mechanisms relevant to AF, including intracellular calcium kinetics, pro-inflammatory cytokine profiles, and the PI3K/Akt/eNOS signaling cascade, as well as modify the expression of certain microRNA levels, resulting in reduced incidence and severity of AF in both preclinical and clinical studies[85–91]. On the other hand, retinoids, such as fenretinide and tretinoin, have less evidence in the context of AF. However, it has been shown that these molecules can improve myocardial energy metabolism through modulation of pyruvate dehydrogenase kinase, decreasing the incidence of ventricular arrhythmias in murine models of ischemia-reperfusion[92–94]. The variety of compounds identified and their multiple mechanisms of action highlight the complexity of the mechanisms related to the development and perpetuation of this arrhythmia. Although some of the compounds identified in our gene-drug analysis have side effects or contraindications, these may not be relevant for patient populations likely to be treated for AF or may not be severe enough to contraindicate the drug for this purpose[95,96]. Published studies aiming to assess the benefits of some of these molecules suffer from important limitations in their design, highlighting a pressing need for double-blind randomized controlled trials designed to assess AF incidence as a primary outcome and that make use of tools such as Holter monitoring or loop recording to improve the ability to identify potential silent AF episodes[84]. Overall, gene-drug analyses such as those provided here, can provide insights into biological mechanism and can be an important hypothesis generation tool for drug repurposing efforts

Strengths and limitations

As a meta-analysis with a standard bioinformatics analysis process, our study was strengthened by the increased sample size compared to individual studies, as well as the feasibility of pooling heterogeneous data, taking into account relevant factors such as the sampling/technical variability and variability derived from significant demographic and clinical covariates. Furthermore, our disease scoring metric enabled cross-study gene expression comparability. Significant directional consistency across studies supported the robustness of our differential gene regulation findings. Notably, including both atrial chambers in our meta-analytic framework provided a granular, chamber-specific perspective on AF pathophysiology, while comprehensive functional analyses yielded actionable insights into the implicated molecular processes.

Notwithstanding its strengths, our study is subject to several limitations. First, the lack of individual patient data in most incorporated studies limited the possibility for subgroup analysis, and precluded optimal covariate adjustment. Additionally, the studies that met our inclusion criteria included predominantly patients with persistent or permanent AF. As we lack appropriate sample size for analysis of other AF subtypes, such as paroxysmal AF, we are unable to state whether our findings generalize to those populations. Moreover, the low proportion of dual-chamber samples and

disparities in gene coverage and sample size between the LAA and RAA impede direct chamber-to-chamber comparability. Another limitation relates to the meta-analysis process itself, as our gene standardization approach could only partially eliminate technical heterogeneity arising from using varied platforms. Lastly, all of the gene enrichment and gene-drug analyses presented here are computational and require further investigation for validation of biological signals and clinical relevance. Nevertheless, the current evidence suggests a potential cardiovascular benefit of all compounds identified in the present analysis at the functional or structural level, highlighting the value of this meta-analytical approach to draw attention to compounds with high repurposing potential.

Implications for Clinical Practice and Future Directions

The consensus transcriptional signatures derived from this meta-analysis, which consolidates the available knowledge from genome-wide transcriptomics, offer an opportunity to refine the current clinical approach to AF. Identifying consistently dysregulated genes and pathways across heterogeneous patient samples strengthens the foundation for targeted diagnostic markers and provides a molecular framework for building personalized treatment strategies. For instance, elucidating potential roles for lipid-lowering agents, antioxidants, ion channels and retinoids in mitigating pathway dysregulation highlights an opportunity for drug repurposing, thereby offering avenues for clinical testing.

Despite these advances, it is paramount to address the current study's limitations to foster future research directions. The scarcity of individual patient-level data necessitates further studies to confirm these findings in diverse patient populations, focusing on subgroup analyses to determine the potential effect of concomitant comorbid conditions and to characterize the conserved gene expression patterns in AF across the different types (paroxysmal, persistent, and permanent) to better understand the mechanisms potentially associated with arrhythmia progression and perpetuation. Future studies should also aim to validate our drug-gene interaction findings through rigorous *in vitro* and *in vivo* assessments, ensuring the practical utility of these candidate compounds. Thus, while we believe our study marks a significant step forward in our understanding of AF, it also delineates the critical avenues for future research aiming to translate these molecular insights into actionable clinical interventions.

Acknowledgments
The authors thank Ricardo Ramírez Flores for the valuable feedback and critical assessment of the manuscript.

Disclosure of Interest

None of the authors have potential conflicts of interest or disclosures to report. The authors assert that all figures and illustrations contained in the manuscript are original and do not necessitate permission for reprint.

Data Availability

The study data are available in the supplementary material. The code used to generate the results and the processed data is available in GitHub (https://github.com/thelevinsonlab/AF_CS_MA).

Ethical Approval

Ethical approval was not required.

Registration Number

The study was registered in the International Prospective Register of Systematic Reviews (PROSPERO) under the record code CRD42023399021. Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID= CRD42023399021.

References

[1] Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Int J Stroke 2021;16:217–21.

[2] Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42:373–498.

[3] Delaney JA, Yin X, Fontes JD, Wallace ER, Skinner A, Wang N, et al. Hospital and clinical care costs associated with atrial fibrillation for Medicare beneficiaries in the Cardiovascular Health Study and the Framingham Heart Study. SAGE Open Med 2018;6:2050312118759444.

[4] Farmakis D, Chrysohoou C, Giamouzis G, Giannakoulas G, Hamilos M, Naka K, et al. The management of atrial fibrillation in heart failure: an expert panel consensus. Heart Fail Rev 2021;26:1345–58.

[5] Kraft M, Büscher A, Wiedmann F, L'hoste Y, Haefeli WE, Frey N, et al. Current Drug Treatment Strategies for Atrial Fibrillation and TASK-1 Inhibition as an Emerging Novel Therapy Option. Front Pharmacol 2021;12:638445.

[6] Reiffel JA. Selected Advancements in the Management of Atrial Fibrillation from the Year 2021. J Innov Card Rhythm Manag 2022;13:4840–6.

[7] Sohinki D, Stavrakis S. New approaches for treating atrial fibrillation: Focus on autonomic modulation. Trends Cardiovasc Med 2020;30:433–9.

[8] Chung MK, Youn Wass SJ, Barnard J. Insights From Atrial Fibrillation Genomics: From Bedside to Bench and Back Again. Cardiol Rev 2019;27:302–7.

[9] Lin H, Yin X, Lunetta KL, Dupuis J, McManus DD, Lubitz SA, et al. Whole blood gene expression and atrial fibrillation: the Framingham Heart Study. PLoS One 2014;9:e96794.

[10] van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD, et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure.

Proc Natl Acad Sci U S A 2006;103:18255–60.

[11] Dawson K, Wakili R, Ordög B, Clauss S, Chen Y, Iwasaki Y, et al. MicroRNA29: a mechanistic contributor and potential biomarker in atrial fibrillation. Circulation 2013;127:1466–75, 1475e1–28.

[12] Cong H, Li X, Ma L, Jiang H, Mao Y, Xu M. Angiotensin II receptor type 1 is upregulated in atrial tissue of patients with rheumatic valvular disease with atrial fibrillation. J Thorac Cardiovasc Surg 2010;140:298–304.

[13] Jiang Y-Y, Hou H-T, Yang Q, Liu X-C, He G-W. Chloride Channels are Involved in the Development of Atrial Fibrillation - A Transcriptomic and proteomic Study. Sci Rep 2017;7:10215.

[14] Steenman M. Insight into atrial fibrillation through analysis of the coding transcriptome in humans. Biophys Rev 2020;12:817–26.

[15] Shoemaker MB, Roden DM. Atrial Fibrillation Is a Complex Trait: Very Complex. Circ Res 2020;127:244–6.

[16] Tucker NR, Clauss S, Ellinor PT. Common variation in atrial fibrillation: navigating the path from genetic association to mechanism. Cardiovasc Res 2016;109:493–501.

[17] Sung J, Wang Y, Chandrasekaran S, Witten DM, Price ND. Molecular signatures from omics data: from chaos to consensus. Biotechnol J 2012;7:946–57.

[18] Tajti F, Kuppe C, Antoranz A, Ibrahim MM, Kim H, Ceccarelli F, et al. A Functional Landscape of CKD Entities From Public Transcriptomic Data. Kidney Int Rep 2020;5:211–24.

[19] Ramirez Flores RO, Lanzer JD, Holland CH, Leuschner F, Most P, Schultz J-H, et al. Consensus Transcriptional Landscape of Human End-Stage Heart Failure. J Am Heart Assoc 2021;10:e019667.

[20] Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71.

[21] Glisic M, Raguindin PF, Gemperli A, Taneri PE, Salvador D Jr, Voortman T, et al. A 7-Step Guideline for Qualitative Synthesis and Meta-Analysis of Observational Studies in Health Sciences. Public Health Rev 2023;44:1605454.

[22] Muka T, Glisic M, Milic J, Verhoog S, Bohlius J, Bramer W, et al. A 24-step guide on how to design, conduct, and successfully publish a systematic review and meta-analysis in medical research. Eur J Epidemiol 2020;35:49–60.

[23] Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc 1995;57:289–300.

[24] Plaisier SB, Taschereau R, Wong JA, Graeber TG. Rank-rank hypergeometric overlap: identification of statistically significant overlap between gene-expression signatures. Nucleic Acids Res 2010;38:e169.

[25] Adam O, Lavall D, Theobald K, Hohl M, Grube M, Ameling S, et al. Rac1-induced connective tissue growth factor regulates connexin 43 and N-cadherin expression in atrial fibrillation. J Am Coll Cardiol 2010;55:469–80.

[26] Assum I, Krause J, Scheinhardt MO, Müller C, Hammer E, Börschel CS, et al. Tissue-specific multi-omics analysis of atrial fibrillation. Nat Commun 2022;13:441.

[27] Barth AS, Merk S, Arnoldi E, Zwermann L, Kloos P, Gebauer M, et al. Reprogramming of the human atrial transcriptome in permanent atrial fibrillation: expression of a ventricular-like genomic signature. Circ Res 2005;96:1022–9.

[28] Chen H-X, Li M-Y, Jiang Y-Y, Hou H-T, Wang J, Liu X-C, et al. Role of the PPAR pathway in atrial fibrillation associated with heart valve disease: transcriptomics and proteomics in human atrial tissue. Signal Transduct Target Ther 2020;5:4.

[29] Chiang DY, Zhang M, Voigt N, Alsina KM, Jakob H, Martin JF, et al. Identification of microRNA-mRNA dysregulations in paroxysmal atrial fibrillation. Int J Cardiol 2015;184:190–7.

[30] Darkow E, Nguyen TT, Stolina M, Kari FA, Schmidt C, Wiedmann F, et al. Small Conductance Ca^{2+}-Activated K^+ (SK) Channel mRNA Expression in Human Atrial and Ventricular Tissue: Comparison Between Donor, Atrial Fibrillation and Heart Failure Tissue. Front Physiol 2021;12:650964.

[31] Çubukçuoğlu Deniz G, Durdu S, Doğan Y, Erdemli E, Özdağ H, Akar AR. Molecular Signatures

of Human Chronic Atrial Fibrillation in Primary Mitral Regurgitation. Cardiovasc Ther 2021;2021:5516185.

[32] Deshmukh A, Barnard J, Sun H, Newton D, Castel L, Pettersson G, et al. Left atrial transcriptional changes associated with atrial fibrillation susceptibility and persistence. Circ Arrhythm Electrophysiol 2015;8:32–41.

[33] Doñate Puertas R, Meugnier E, Romestaing C, Rey C, Morel E, Lachuer J, et al. Atrial fibrillation is associated with hypermethylation in human left atrium, and treatment with decitabine reduces atrial tachyarrhythmias in spontaneously hypertensive rats. Transl Res 2017;184:57–67.e5.

[34] Herrera-Rivero M, Gandhi S, Witten A, Ghalawinji A, Schotten U, Stoll M. Cardiac chamber-specific genetic alterations suggest candidate genes and pathways implicating the left ventricle in the pathogenesis of atrial fibrillation. Genomics 2022;114:110320.

[35] Hsu J, Gore-Panter S, Tchou G, Castel L, Lovano B, Moravec CS, et al. Genetic Control of Left Atrial Gene Expression Yields Insights into the Genetic Susceptibility for Atrial Fibrillation. Circ Genom Precis Med 2018;11:e002107.

[36] Kertai MD, Qi W, Li Y-J, Lombard FW, Liu Y, Smith MP, et al. Gene signatures of postoperative atrial fibrillation in atrial tissue after coronary artery bypass grafting surgery in patients receiving β-blockers. J Mol Cell Cardiol 2016;92:109–15.

[37] Kharlap MS, Timofeeva AV, Goryunova LE, Khaspekov GL, Dzemeshkevich SL, Ruskin VV, et al. Atrial appendage transcriptional profile in patients with atrial fibrillation with structural heart diseases. Ann N Y Acad Sci 2006;1091:205–17.

[38] Kim N-H, Ahn Y, Oh SK, Cho JK, Park HW, Kim Y-S, et al. Altered patterns of gene expression in response to chronic atrial fibrillation. Int Heart J 2005;46:383–95.

[39] Kim YH, Lim DS, Lee JH, Shim WJ, Ro YM, Park GH, et al. Gene expression profiling of oxidative stress on atrial fibrillation in humans. Exp Mol Med 2003;35:336–49.

[40] Lal JC, Mao C, Zhou Y, Gore-Panter SR, Rennison JH, Lovano BS, et al. Transcriptomics-based network medicine approach identifies metformin as a repurposable drug for atrial fibrillation. Cell Rep Med 2022;3:100749.

[41] Lamirault G, Gaborit N, Le Meur N, Chevalier C, Lande G, Demolombe S, et al. Gene expression profile associated with chronic atrial fibrillation and underlying valvular heart disease in man. J Mol Cell Cardiol 2006;40:173–84.

[42] Lipovsky CE, Jimenez J, Guo Q, Li G, Yin T, Hicks SC, et al. Chamber-specific transcriptional responses in atrial fibrillation. JCI Insight 2020;5. https://doi.org/10.1172/jci.insight.135319.

[43] Mei B, Liu H, Yang S, Liang M-Y, Yue Y, Huang S-Q, et al. Long non-coding RNA expression profile in permanent atrial fibrillation patients with rheumatic heart disease. Eur Rev Med Pharmacol Sci 2018;22:6940–7.

[44] Ohki R, Yamamoto K, Ueno S, Mano H, Misawa Y, Fuse K, et al. Gene expression profiling of human atrial myocardium with atrial fibrillation by DNA microarray analysis. Int J Cardiol 2005;102:233–8.

[45] Larupa Santos J, Rodríguez I, S Olesen M, Hjorth Bentzen B, Schmitt N. Investigating gene-microRNA networks in atrial fibrillation patients with mitral valve regurgitation. PLoS One 2020;15:e0232719.

[46] Sun H, Shao Y. Transcriptome analysis reveals key pathways that vary in patients with paroxysmal and persistent atrial fibrillation. Exp Ther Med 2021;21:1–13.

[47] Thomas AM, Cabrera CP, Finlay M, Lall K, Nobles M, Schilling RJ, et al. Differentially expressed genes for atrial fibrillation identified by RNA sequencing from paired human left and right atrial appendages. Physiol Genomics 2019;51:323–32.

[48] Tsai F-C, Lin Y-C, Chang S-H, Chang G-J, Hsu Y-J, Lin Y-M, et al. Differential left-to-right atria gene expression ratio in human sinus rhythm and atrial fibrillation: Implications for arrhythmogenesis and thrombogenesis. Int J Cardiol 2016;222:104–12.

[49] van den Berg NWE, Kawasaki M, Fabrizi B, Nariswari FA, Verduijn AC, Neefs J, et al. Epicardial and endothelial cell activation concurs with extracellular matrix remodeling in atrial fibrillation. Clin Transl Med 2021;11:e558.

[50] Wang R, Bektik E, Sakon P, Wang X, Huang S, Meng X, et al. Integrated Analysis of the microRNA-mRNA Network Predicts Potential Regulators of Atrial Fibrillation in Humans. Cells

2022;11. https://doi.org/10.3390/cells11172629.

[51] Wu N, Li J, Chen X, Xiang Y, Wu L, Li C, et al. Identification of Long Non-Coding RNA and Circular RNA Expression Profiles in Atrial Fibrillation. Heart Lung Circ 2020;29:e157–67.

[52] Yeh Y-H, Kuo C-T, Lee Y-S, Lin Y-M, Nattel S, Tsai F-C, et al. Region-specific gene expression profiles in the left atria of patients with valvular atrial fibrillation. Heart Rhythm 2013;10:383–91.

[53] Zeemering S, Isaacs A, Winters J, Maesen B, Bidar E, Dimopoulou C, et al. Atrial fibrillation in the presence and absence of heart failure enhances expression of genes involved in cardiomyocyte structure, conduction properties, fibrosis, inflammation, and endothelial dysfunction. Heart Rhythm 2022;19:2115–24.

[54] Zhang Y, Ke X, Liu J, Ma X, Liu Y, Liang D, et al. Characterization of circRNA□associated ceRNA networks in patients with nonvalvular persistent atrial fibrillation. Mol Med Rep 2019;19:638–50.

[55] Zhang Y, Shen H, Wang P, Min J, Yu Y, Wang Q, et al. Identification and characterization of circular RNAs in atrial appendage of patients with atrial fibrillation. Exp Cell Res 2020;389:111821.

[56] Zhou J, Gao J, Liu Y, Gu S, Zhang X, An X, et al. Human atrium transcript analysis of permanent atrial fibrillation. Int Heart J 2014;55:71–7.

[57] Zhu X, Tang X, Chong H, Cao H, Fan F, Pan J, et al. Expression Profiles of Circular RNA in Human Atrial Fibrillation With Valvular Heart Diseases. Front Cardiovasc Med 2020;7:597932.

[58] Xu Y, Wu A, Chen J, Song X, Chen M, Liu Q. Limb-Bud and Heart (LBH) Upregulation in Cardiomyocytes under Hypoxia Promotes the Activation of Cardiac Fibroblasts via Exosome Secretion. Mediators Inflamm 2022;2022:8939449.

[59] Gil-Cayuela C, Roselló-LLetí E, Ortega A, Tarazón E, Triviño JC, Martínez-Dolz L, et al. New Altered Non-Fibrillar Collagens in Human Dilated Cardiomyopathy: Role in the Remodeling Process. PLoS One 2016;11:e0168130.

[60] Tian Z, Miyata K, Kadomatsu T, Horiguchi H, Fukushima H, Tohyama S, et al. ANGPTL2 activity in cardiac pathologies accelerates heart failure by perturbing cardiac function and energy metabolism. Nat Commun 2016;7:13016.

[61] Quiles JM, Narasimhan M, Mosbruger T, Shanmugam G, Crossman D, Rajasekaran NS. Identification of transcriptome signature for myocardial reductive stress. Redox Biol 2017;13:568–80.

[62] Yang K-C, Jay PY, McMullen JR, Nerbonne JM. Enhanced cardiac PI3Kα signalling mitigates arrhythmogenic electrical remodelling in pathological hypertrophy and heart failure. Cardiovasc Res 2012;93:252–62.

[63] Al Kury LT, Chacar S, Alefishat E, Khraibi AA, Nader M. Structural and Electrical Remodeling of the Sinoatrial Node in Diabetes: New Dimensions and Perspectives. Front Endocrinol 2022;13:946313.

[64] Fabritz L, Herzig S. Can T-type calcium channels make a change of heart after myocardial infarction? Fiction or fact, and for better or for worse? Cardiovasc Res 2011;91:373–5.

[65] Brown SM, Larsen NK, Thankam FG, Agrawal DK. Fetal cardiomyocyte phenotype, ketone body metabolism, and mitochondrial dysfunction in the pathology of atrial fibrillation. Mol Cell Biochem 2021;476:1165–78.

[66] Kovacic JC, Dimmeler S, Harvey RP, Finkel T, Aikawa E, Krenning G, et al. Endothelial to Mesenchymal Transition in Cardiovascular Disease: JACC State-of-the-Art Review. J Am Coll Cardiol 2019;73:190–209.

[67] Varela M, Colman MA, Hancox JC, Aslanidi OV. Atrial Heterogeneity Generates Re-entrant Substrate during Atrial Fibrillation and Anti-arrhythmic Drug Action: Mechanistic Insights from Canine Atrial Models. PLoS Comput Biol 2016;12:e1005245.

[68] Elliott J, Mainardi L, Rodriguez Matas JF. Cellular heterogeneity and repolarisation across the atria: an in silico study. Med Biol Eng Comput 2022;60:3153–68.

[69] Avula UMR, Melki L, Kushner JS, Liang S, Wan EY. Theoretical Models and Computational Analysis of Action Potential Dispersion for Cardiac Arrhythmia Risk Stratification. Front Cardiovasc Med 2021;8:649489.

[70] Denham NC, Pearman CM, Caldwell JL, Madders GWP, Eisner DA, Trafford AW, et al.

Calcium in the Pathophysiology of Atrial Fibrillation and Heart Failure. Front Physiol 2018;9:1380.

[71] Greiser M, Kerfant B-G, Williams GSB, Voigt N, Harks E, Dibb KM, et al. Tachycardia-induced silencing of subcellular Ca2+ signaling in atrial myocytes. J Clin Invest 2014;124:4759–72.

[72] Kolwicz SC Jr, Purohit S, Tian R. Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes. Circ Res 2013;113:603–16.

[73] Rennison JH, Li L, Lin CR, Lovano BS, Castel L, Wass SY, et al. Atrial fibrillation rhythm is associated with marked changes in metabolic and myofibrillar protein expression in left atrial appendage. Pflugers Arch 2021;473:461–75.

[74] Tu T, Qin F, Bai F, Xiao Y, Ma Y, Li B, et al. Quantitative acetylated proteomics on left atrial appendage tissues revealed atrial energy metabolism and contraction status in patients with valvular heart disease with atrial fibrillation. Front Cardiovasc Med 2022;9:962036.

[75] Mason FE, Pronto JRD, Alhussini K, Maack C, Voigt N. Cellular and mitochondrial mechanisms of atrial fibrillation. Basic Res Cardiol 2020;115:72.

[76] Lenski M, Schleider G, Kohlhaas M, Adrian L, Adam O, Tian Q, et al. Arrhythmia causes lipid accumulation and reduced glucose uptake. Basic Res Cardiol 2015;110:40.

[77] Friedrichs K, Adam M, Remane L, Mollenhauer M, Rudolph V, Rudolph TK, et al. Induction of atrial fibrillation by neutrophils critically depends on CD11b/CD18 integrins. PLoS One 2014;9:e89307.

[78] Rudolph V, Andrié RP, Rudolph TK, Friedrichs K, Klinke A, Hirsch-Hoffmann B, et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat Med 2010;16:470–4.

[79] Mołek P, Ząbczyk M, Malinowski KP, Natorska J, Undas A. Enhanced neutrophil extracellular traps formation in AF patients with dilated left atrium. Eur J Clin Invest 2023;53:e13952.

[80] Lu M, Zhang Y, Liu R, He X, Hou B. Predictive value of neutrophil to lymphocyte ratio for ischemic stroke in patients with atrial fibrillation: A meta-analysis. Front Neurol 2022;13:1029010.

[81] Liu Z, Nguyen Khuong J, Borg Caruana C, Jackson SM, Campbell R, Ramson DM, et al. The Prognostic Value of Elevated Perioperative Neutrophil-Lymphocyte Ratio in Predicting Postoperative Atrial Fibrillation After Cardiac Surgery: A Systematic Review and Meta-Analysis. Heart Lung Circ 2020;29:1015–24.

[82] Shao Q, Chen K, Rha S-W, Lim H-E, Li G, Liu T. Usefulness of Neutrophil/Lymphocyte Ratio as a Predictor of Atrial Fibrillation: A Meta-analysis. Arch Med Res 2015;46:199–206.

[83] Hanna IR, Heeke B, Bush H, Brosius L, King-Hageman D, Dudley SC Jr, et al. Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm 2006;3:881–6.

[84] Oraii A, Vasheghani-Farahani A, Oraii S, Roayaei P, Balali P, Masoudkabir F. Update on the efficacy of statins in primary and secondary prevention of atrial fibrillation. Rev Port Cardiol 2021;40:509–18.

[85] Lin Y-K, Lin F-Z, Chen Y-C, Cheng C-C, Lin C-I, Chen Y-J, et al. Oxidative stress on pulmonary vein and left atrium arrhythmogenesis. Circ J 2010;74:1547–56.

[86] Hemilä H, Suonsyrjä T. Vitamin C for preventing atrial fibrillation in high risk patients: a systematic review and meta-analysis. BMC Cardiovasc Disord 2017;17:49.

[87] Yue H, Zhao X, Liang W, Qin X, Bian L, He K, et al. Curcumin, novel application in reversing myocardial fibrosis in the treatment for atrial fibrillation from the perspective of transcriptomics in rat model. Biomed Pharmacother 2022;146:112522.

[88] Gan M, Zheng T, Shen L, Tan Y, Fan Y, Shuai S, et al. Genistein reverses isoproterenol-induced cardiac hypertrophy by regulating miR-451/TIMP2. Biomed Pharmacother 2019;112:108618.

[89] Lage R, Cebro-Márquez M, Vilar-Sánchez ME, González-Melchor L, García-Seara J, Martínez-Sande JL, et al. Circulating miR-451a Expression May Predict Recurrence in Atrial Fibrillation Patients after Catheter Pulmonary Vein Ablation. Cells 2023;12. https://doi.org/10.3390/cells12040638.

[90] Chong E, Chang S-L, Hsiao Y-W, Singhal R, Liu S-H, Leha T, et al. Resveratrol, a red wine antioxidant, reduces atrial fibrillation susceptibility in the failing heart by PI3K/AKT/eNOS signaling pathway activation. Heart Rhythm 2015;12:1046–56.

[91] Zhang Y, Zhang S, Liu Z, Zhao X, Yuan Y, Sheng L, et al. Resveratrol prevents atrial fibrillation

by inhibiting atrial structural and metabolic remodeling in collagen-induced arthritis rats. Naunyn Schmiedebergs Arch Pharmacol 2018;391:1179–90.

[92] Holloway C, Zhong G, Kim Y-K, Ye H, Sampath H, Hammerling U, et al. Retinoic acid regulates pyruvate dehydrogenase kinase 4 (Pdk4) to modulate fuel utilization in the adult heart: Insights from wild-type and β-carotene 9',10' oxygenase knockout mice. FASEB J 2022;36:e22513.

[93] Kang JX, Leaf A. Protective effects of All-trans-retinoic acid against cardiac arrhythmias induced by isoproterenol, lysophosphatidylcholine or ischemia and reperfusion. J Cardiovasc Pharmacol 1995;26:943–8.

[94] Marino A, Sakamoto T, Tang X-H, Gudas LJ, Levi R. A Retinoic Acid β2-Receptor Agonist Exerts Cardioprotective Effects. J Pharmacol Exp Ther 2018;366:314–21.

[95] Kapała J, Lewandowska J, Placek W, Owczarczyk-Saczonek A. Adverse Events in Isotretinoin Therapy: A Single-Arm Meta-Analysis. Int J Environ Res Public Health 2022;19. https://doi.org/10.3390/ijerph19116463.

[96] Nanau RM, Neuman MG. Adverse drug reactions induced by valproic acid. Clin Biochem 2013;46:1323–38.

[97] Almoghrabi OA, Brungardt JG, Helmer SD, Reyes JM, Grizzell BE. Efficacy of Intravenous Acetaminophen as Adjunct Post-Operative Analgesic in Cardiac Surgery: A Retrospective Study. Kans J Med 2020;13:143–6.

[98] Chang J-H, Cheng P-Y, Hsu C-H, Chen Y-C, Hong P-D. Effects of Acetaminophen on Left Atrial Contractility. Acta Cardiol Sin 2016;32:485–90.

[99] Li W, Li W, Leng Y, Xiong Y, Xue R, Chen R, et al. Mechanism of N-acetylcysteine in alleviating diabetic myocardial ischemia reperfusion injury by regulating PTEN/Akt pathway through promoting DJ-1. Biosci Rep 2020;40. https://doi.org/10.1042/BSR20192118.

[100] Khan SA, Campbell AM, Lu Y, An L, Alpert JS, Chen QM. N-Acetylcysteine for Cardiac Protection During Coronary Artery Reperfusion: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Cardiovasc Med 2021;8:752939.

[101] Gu W-J, Wu Z-J, Wang P-F, Aung LHH, Yin R-X. N-Acetylcysteine supplementation for the prevention of atrial fibrillation after cardiac surgery: a meta-analysis of eight randomized controlled trials. BMC Cardiovasc Disord 2012;12:10.

[102] Chen F, Hadfield JM, Berzingi C, Hollander JM, Miller DB, Nichols CE, et al. N-acetylcysteine reverses cardiac myocyte dysfunction in a rodent model of behavioral stress. J Appl Physiol 2013;115:514–24.

[103] Giam B, Chu P-Y, Kuruppu S, Smith AI, Horlock D, Kiriazis H, et al. N-acetylcysteine attenuates the development of cardiac fibrosis and remodeling in a mouse model of heart failure. Physiol Rep 2016;4. https://doi.org/10.14814/phy2.12757.

[104] Hameed I, Malik S, Nusrat K, Siddiqui OM, Khan MO, Mahmood S, et al. Effect of vitamin D on postoperative atrial fibrillation in patients who underwent coronary artery bypass grafting: A systematic review and meta-analysis. J Cardiol 2023;82:220–4.

[105] Tamayo M, Manzanares E, Bas M, Martín-Nunes L, Val-Blasco A, Jesús Larriba M, et al. Calcitriol (1,25-dihydroxyvitamin D3) increases L-type calcium current via protein kinase A signaling and modulates calcium cycling and contractility in isolated mouse ventricular myocytes. Heart Rhythm 2017;14:432–9.

[106] Tamayo M, Martin-Nunes L, Val-Blasco A, Piedras MJ, Larriba MJ, Gómez-Hurtado N, et al. Calcitriol, the Bioactive Metabolite of Vitamin D, Increases Ventricular K+ Currents in Isolated Mouse Cardiomyocytes. Front Physiol 2018;9:1186.

[107] Liu G-Z, Hou T-T, Yuan Y, Hang P-Z, Zhao J-J, Sun L, et al. Fenofibrate inhibits atrial metabolic remodelling in atrial fibrillation through PPAR-α/sirtuin 1/PGC-1α pathway. Br J Pharmacol 2016;173:1095–109.

[108] Bukhari IA, Almotrefi AA, Mohamed OY, Al-Masri AA, Sheikh SA. Protective effect of fenofibrate against ischemia-/reperfusion-induced cardiac arrhythmias in isolated rat hearts. Fundam Clin Pharmacol 2018;32:141–6.

[109] Funamoto M, Sunagawa Y, Katanasaka Y, Kato T, Funada J, Ajiro Y, et al. Effects of high-absorption curcumin for the prevention of hypertensive heart disease: a double-blind, placebo-controlled, randomized clinical study. Eur Heart J Open 2022;2:oeac057.

[110]   Shahcheraghi SH, Salemi F, Peirovi N, Ayatollahi J, Alam W, Khan H, et al. Nrf2 Regulation by Curcumin: Molecular Aspects for Therapeutic Prospects. Molecules 2021;27. https://doi.org/10.3390/molecules27010167.

[111]   Song L, Zhang Z-F, Hu L-K, Zhang P-H, Cao Z-Z, Liu Z-P, et al. Curcumin, a Multi-Ion Channel Blocker That Preferentially Blocks Late Na+ Current and Prevents I/R-Induced Arrhythmias. Front Physiol 2020;11:978.

[112]   Li Y, Huang T, Zheng Y, Muka T, Troup J, Hu FB. Folic Acid Supplementation and the Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc 2016;5. https://doi.org/10.1161/JAHA.116.003768.

[113]   Kubota Y, Alonso A, Heckbert SR, Norby FL, Folsom AR. Homocysteine and Incident Atrial Fibrillation: The Atherosclerosis Risk in Communities Study and the Multi-Ethnic Study of Atherosclerosis. Heart Lung Circ 2019;28:615–22.

[114]   Li W, Tang R, Ouyang S, Ma F, Liu Z, Wu J. Folic acid prevents cardiac dysfunction and reduces myocardial fibrosis in a mouse model of high-fat diet-induced obesity. Nutr Metab 2017;14:68.

[115]   De Gregorio C, Marini H, Alibrandi A, Di Benedetto A, Bitto A, Adamo EB, et al. Genistein Supplementation and Cardiac Function in Postmenopausal Women with Metabolic Syndrome: Results from a Pilot Strain-Echo Study. Nutrients 2017;9. https://doi.org/10.3390/nu9060584.

[116]   Deodato B, Altavilla D, Squadrito G, Campo GM, Arlotta M, Minutoli L, et al. Cardioprotection by the phytoestrogen genistein in experimental myocardial ischaemia-reperfusion injury. Br J Pharmacol 1999;128:1683–90.

[117]   Liew R, Macleod KT, Collins P. Novel stimulatory actions of the phytoestrogen genistein: effects on the gain of cardiac excitation-contraction coupling. FASEB J 2003;17:1307–9.

[118]   Fu Y, Hu N, Cao M, Li W-F, Yang X-R, Gao J-L, et al. Anthelmintic niclosamide attenuates pressure-overload induced heart failure in mice. Eur J Pharmacol 2021;912:174614.

[119]   Balgi AD, Fonseca BD, Donohue E, Tsang TCF, Lajoie P, Proud CG, et al. Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling. PLoS One 2009;4:e7124.

[120]   Gao J-L, Zhao J, Zhu H-B, Peng X, Zhu J-X, Ma M-H, et al. Characterizations of mitochondrial uncoupling induced by chemical mitochondrial uncouplers in cardiomyocytes. Free Radic Biol Med 2018;124:288–98.

[121]   Romero-Becerra R, Santamans AM, Folgueira C, Sabio G. p38 MAPK Pathway in the Heart: New Insights in Health and Disease. Int J Mol Sci 2020;21. https://doi.org/10.3390/ijms21197412.

[122]   Surinkaew S, Kumphune S, Chattipakorn S, Chattipakorn N. Inhibition of p38 MAPK during ischemia, but not reperfusion, effectively attenuates fatal arrhythmia in ischemia/reperfusion heart. J Cardiovasc Pharmacol 2013;61:133–41.

[123]   Liao J, Wu Q, Qian C, Zhao N, Zhao Z, Lu K, et al. TRPV4 blockade suppresses atrial fibrillation in sterile pericarditis rats. JCI Insight 2020;5. https://doi.org/10.1172/jci.insight.137528.

[124]   Zechner D, Thuerauf DJ, Hanford DS, McDonough PM, Glembotski CC. A role for the p38 mitogen-activated protein kinase pathway in myocardial cell growth, sarcomeric organization, and cardiac-specific gene expression. J Cell Biol 1997;139:115–27.

[125]   Fang W-T, Li H-J, Zhang H, Jiang S. The role of statin therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Br J Clin Pharmacol 2012;74:744–56.

[126]   Chen J, Nagasawa Y, Zhu B-M, Ohmori M, Harada K-I, Fujimura A, et al. Pravastatin prevents arrhythmias induced by coronary artery ischemia/reperfusion in anesthetized normocholesterolemic rats. J Pharmacol Sci 2003;93:87–94.

[127]   Beri A, Contractor T, Khasnis A, Thakur R. Statins and the reduction of sudden cardiac death: antiarrhythmic or anti-ischemic effect? Am J Cardiovasc Drugs 2010;10:155–64.

[128]   Niessner A, Steiner S, Speidl WS, Pleiner J, Seidinger D, Maurer G, et al. Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo. Atherosclerosis 2006;189:408–13.

[129]   Buber J, Goldenberg I, Moss AJ, Wang PJ, McNitt S, Hall WJ, et al. Reduction in life-

threatening ventricular tachyarrhythmias in statin-treated patients with nonischemic cardiomyopathy enrolled in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy). J Am Coll Cardiol 2012;60:749–55.

[130]   Vyas AK, Guo H, Moss AJ, Olshansky B, McNitt SA, Hall WJ, et al. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 2006;47:769–73.

[131]   Scholz B, Schulte JS, Hamer S, Himmler K, Pluteanu F, Seidl MD, et al. HDAC (Histone Deacetylase) Inhibitor Valproic Acid Attenuates Atrial Remodeling and Delays the Onset of Atrial Fibrillation in Mice. Circ Arrhythm Electrophysiol 2019;12:e007071.

[132]   Tian S, Lei I, Gao W, Liu L, Guo Y, Creech J, et al. HDAC inhibitor valproic acid protects heart function through Foxm1 pathway after acute myocardial infarction. EBioMedicine 2019;39:83–94.

[133]   Rutigliano HM. Effects of Pregnancy and Progesterone on Atrial Fibrillation 2023. https://doi.org/10.26078/y1a7-5f14.

[134]   Liang S, Sun Y-S, Li L, Long Y, Wang M, Yang H-Z, et al. Progesterone Changes the Pregnancy-Induced Adaptation of Cardiomyocyte Kv2.1 Channels via MicroRNA-29b. Cardiovasc Ther 2022;2022:7145699.

[135]   Ma J, Hong K, Wang H-S. Progesterone Protects Against Bisphenol A-Induced Arrhythmias in Female Rat Cardiac Myocytes via Rapid Signaling. Endocrinology 2017;158:778–90.

TABLES

Table 1. General characteristics of the included studies.

First Author	Year	Country	Total Sample	AF Patients	SR Patients	AF Types Evaluated	Sample Collection Context	Sample Sources	Technology	Platform
Adam O, et al[25]	2010	Germany	10	5	5	Permanent	Valve replacement surgery	Left atrial appendage	Microarrays	Affymetrix HGU133-Plus 2.0
Assum I, et al[26]	2022	Germany	78	10	68	Not reported	Coronary Artery Bypass Graft surgery	Right atrial appendage	Microarrays	Affymetrix Human Gene 2.0 ST Array
Barth AS, et al[27]	2005	Germany	30	10	20	Permanent	Valve replacement surgery; Coronary Artery Bypass Graft surgery	Right atrial appendage	Microarrays	Affymetrix Human Genome U133A Array
Chen HX, et al[28]	2020	China	62	36	26	Persistent	Valve replacement surgery	Left atrial appendage; Right atrial appendage	RNA-Seq	Illumina HiSeqTM 2000
Chiang DY, et al[29]	2015	Germany	8	4	4	Paroxysmal	Valve replacement surgery; Coronary Artery Bypass Graft surgery	Right atrial appendage	RNA-Seq	Ion Proton™ System
Darkow E, et al[30]	2021	Germany	25	6	19	Permanent	Valve replacement surgery; Coronary Artery Bypass Graft surgery	Right atrial appendage	RNA-Seq	Illumina HiSeq4000
Deniz G, et al[31]	2021	Turkey	31	15	16	Persistent	Valve replacement surgery	Left atrial appendage; Right atrial appendage	Microarrays	Affymetrix HGU133-Plus 2.0
Deshmukh A, et al[32]	2015	USA	239	207	32	Paroxysmal;Permanent	Valve replacement surgery; Coronary Artery Bypass Graft surgery	Left atrial appendage	Microarrays	Illumina HT-12 Expression BeadChip
Doñate-Puertas R, et al[33]	2017	France	6	4	2	Paroxysmal; Persistent; Permanent	Valve replacement surgery	Left atrial appendage	Microarrays	Human Genome U133A 2.0 Array

Herrera-Rivero M, et al[34]	2022	Netherlands	8	5	3	Paroxysmal; Persistent	Valve replacement surgery; Coronary Artery Bypass Graft surgery; Heart transplantation	Left atrial appendage; Right atrial appendage; Ventricles	RNA-Seq	Illumina NextSeq500
Hsu J, et al.[35]	2018	USA	265	130	135	Not reported	Valve replacement surgery; Coronary Artery Bypass Graft surgery	Left atrial appendage	RNA-Seq	Illumina HiSeq 2000
Jiang YY, et al[13]	2017	China	5	3	2	Persistent; Permanent	Valve replacement surgery	Left atrial appendage; Right atrial appendage	RNA-Seq	Illumina HiSeqTM 2000
Kertai M.D. et al[36]	2016	USA	45	13	32	Not reported	Coronary Artery Bypass Graft surgery	Right atrial appendage	Microarrays	Illumina HT-12 Expression BeadChip
Kharlap MS, et al[37]	2006	Russia	22	12	10	Paroxysmal; Persistent	Valve replacement surgery; Coronary Artery Bypass Graft surgery	Right atrial appendage	Microarrays	AtlasTM Human cDNA Expression Arrays (Clontech)
Kim NH, et al[38]	2005	Korea	18	9	9	Persistent	Valve replacement surgery	Left atrial appendage	Microarrays	TwinChip Human-8K Digital Genomics cDNA microarray
Kim YH, et al[39]	2003	Korea	52	26	26	Permanent	Valve replacement surgery	Right atrial appendage	Microarrays	Research Genetics, Inc., Huntsville, AL
Lal JC, et al[40]	2022	USA	280	136	144	Not reported	Valve replacement surgery; Coronary Artery Bypass Graft surgery; Heart transplantation	Left atrial appendage	RNA-Seq	Illumina HiSeq 2000
Lamirault G, et al[41]	2006	France	29	11	18	Permanent	Valve replacement surgery; Coronary Artery Bypass Graft surgery	Right atrial appendage	Microarrays	In-House
Lipovsky CE, et al[42]	2020	USA	49	13	36	Not reported	Valve replacement surgery; Coronary Artery Bypass Graft surgery; Heart transplantation	Left atrial appendage; Pulmonary veins; Right atrial appendage; Ventricles	RNA-Seq	Illumina HiSeq 2500
Mei B, et al[43]	2018	China	6	3	3	Permanent	Valve replacement surgery	Right atrial appendage	Microarrays	Affymetrix Human Gene 2.0 ST Array

Ohki R, et al[44]	2005	Japan	17	7	10	Not reported	Valve replacement surgery; Coronary Artery Bypass Graft surgery	Right atrial appendage	Microarrays	Human Genome U95A Set
Santos JL, et al[45]	2020	Denmark	12	6	6	Persistent; Permanent	Valve replacement surgery	Right atrial appendage	RNA-Seq	Illumina HiSeq 2500
Sun H, et al[46]	2021	China	9	6	3	Paroxysmal; Persistent	Heart transplantation	Left atrial appendage	RNA-Seq	Illumina HiSeq X ten
Thomas A, et al[47]	2019	England	10	5	5	Permanent	Valve replacement surgery; Coronary Artery Bypass Graft surgery	Left atrial appendage; Right atrial appendage	RNA-Seq	Illumina NextSeq500
Tsai F, et al[48]	2016	Taiwan	13	7	6	Persistent	Valve replacement surgery; Coronary Artery Bypass Graft surgery	Left atrial appendage; Right atrial appendage	Microarrays	Affymetrix HGU133-Plus 2.0
Van den Berg N, et al[49]	2021	Netherlands	64	42	22	Paroxysmal; Persistent	Valve replacement surgery; Coronary Artery Bypass Graft surgery	Left atrial appendage	RNA-Seq	Illumina NovaSeq 6000
Wang R, et al[50]	2022	China	5	3	2	Persistent	Valve replacement surgery; Other	Right atrial appendage	RNA-Seq	Illumina Hiseq X platform
Wu N, et al[51]	2020	China	14	7	7	Not reported	Valve replacement surgery; Other	Right atrial appendage	RNA-Seq	Ion Proton System
Yeh Y, et al[52]	2013	Taiwan	19	16	3	Persistent	Valve replacement surgery	Left atrial appendage; Other	Microarrays	Human Genome U133A 2.0 Array
Zeemering S, et al[53]	2022	Multiple European Countries	195	104	91	Paroxysmal; Persistent; Permanent	Valve replacement surgery	Left atrial appendage; Right atrial appendage	RNA-Seq	Illumina NextSeq500
Zhang Y, et al[54]	2019	China	8	4	4	Persistent	Surgical Ablation of Atrial Fibrillation	Left atrial appendage	RNA-Seq	Illumina Hiseq X10 platform
Zhang Y, et al[55]	2020	China	15	9	6	Persistent	Valve replacement surgery	Left atrial appendage; Right atrial appendage	RNA-Seq	Illumina Hiseq 4000

Zhou J, et al[56]	2014	China	11	7	4	Permanent	Coronary Artery Bypass Graft surgery; Heart transplantation	Left atrial appendage	Microarrays	Agilent Human 4x44K Gene Expression Microarray
Zhu X, et al[57]	2020	China	20	10	10	Persistent	Valve replacement surgery	Left atrial appendage	RNA-Seq	Illumina HiSeqTM 2500

Table 2. Summary of the available evidence on potential mechanisms and benefit of the manually curated compounds in atrial fibrillation, cardiac arrhythmias and cardiac function.

Compound	Suggested Molecular Mechanisms							Evidence of Benefit from Association Studies									References
								AF			Non-AF			Other			
	Calcium Handling	Fibroblast Activation	Oxidative Stress	AP & Ion Channels	Inflammation	Myocardial Energetics	Other	AF in preclinical studies	AF in non-randomized clinical studies	AF in randomized studies	Other arrhythmias in preclinical studies	Other arrhythmias in non-randomized studies	Other arrhythmias in randomized studies	Overall cardiac function/structure (preclinical)	Overall cardiac function/structure (non-randomized clinical)	Overall cardiac function/structure (randomized clinical)	

	[refs]
Acetaminophen	[97,98]
Acetylcysteine (N-acetylcysteine)	[99–103]
Ascorbic Acid	[85,86]
Calcitriol	[104–106]
PPAR-α agonists (Clorfibrate & Pirinixic Acid)	[83,107,108]
Curcumin	[87,109–111]
Retinoids (Fenretinide & Tretinoin)	[92–94]
Folic Acid	[112–114]
Genistein	[88,89,115–117]
Niclosamide	[118–120]
Resveratrol	[90,91]
SB 203580	[121–124]
Statins (Pravastatin)	[125–130]
Valproic Acid	[131,132]
Progesterone	[133–135]

Red boxes represent a direct effect in each of the molecular mechanism categories, whereas orange boxes represent evidence of an indirect effect. Blue boxes represent the availability of evidence suggesting a potential benefit in the context of cardiac arrhythmias and cardiac function/structure for each compound.